The pharmaceutical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant potential in clinical trials for addressing obesity. Unlike some available weight loss treatments, retatrutide appears to offer a greater substant